Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"sunitinib"”.
-
Exploring alternative dosing schedules of sunitinib in cancer treatment
Contains fulltext : 317867.pdf (Publisher’s version ) (Closed access)
-
Sunitinib-Induced Cardiotoxicity Exposes Microvascular and Metabolic Derangements In The Failing Heart
… is the small molecular receptor tyrosine kinase sunitinib. Sunitinib was developed in the early 2000’s as part of a wave of antiangiogenic drugs that target the vascular endothelial growth factor receptors and platelet-derived growth factor receptors. Unfortunately, up to 47% of patients treated …
-
Axl RTK and microRNAs in urogenital cancers
… investigating the role of Gas6/Axl signaling in Sunitinib treatment in ccRCC. Axl has been linked to resistance to targeted therapies in cancer. Sunitinib is an angiogenesis-inhibiting drug used in treatment of advanced ccRCC, however disease progression eventually occurs in many patients. We …
-
Monitorización farmacoterapéutica de inhibidores de tirosina quinasa en pacientes oncológicos.
… imatinib, lapatinib, pazopanib, sorafenib y sunitinib) y las consecuentes modificaciones de dosis realizadas. Material y método: estudio analítico retrospectivo en el que se han incluido 74 pacientes en tratamiento con TKIs, a los que se les ha realizado TDM y recomendación de ajuste …
-
First-order statistical speckle models improve robustness and reproducibility of contrast-enhanced ultrasound perfusion estimates
… PDX model is to screen RCC patients for de novo sunitinib resistance. The analysis of the first-order speckle statistics of contrast-enhanced ultrasound cine loops provides more robust and reproducible estimates of tumor blood perfusion than conventional image analysis. Theoretically this form of …
-
Quantification Of Vascular Parametric Indices Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
… the vascular changes induced by various doses of sunitinib in tumor-bearing kidneys and normal contralateral kidneys. Usually, only the first minute of data are used for processing to calculate the initial area under the curve (IAUC) and/or the median value of cumulative initial area under the …
-
Thiazolidinone-isatin hybrids as multi-target anticancer agents
… of FDA approved kinase inhibitors, including Sunitinib and Nintedanib, the second project aims to the design and synthesis of indolinone derivates able to inhibit different kinases. In this respect, I have been visiting researcher at the University College Cork, in Ireland, under the …
-
Quantitative analysis of signaling networks in proneural glioblastoma
… in our murine GBM model after treatment with sunitinib, an inhibitor of its driver receptor tyrosine kinase, PDGFRA. Treatment increased survival but lead to a morphological change causing a more invasive phenotype. Pro-migratory signaling was characterized by mass spectrometry, such as …
-
Study Of The Photodegradation And Photostability Of Anti-Cancer Drugs In Different Media Towards The Development Of Both New Actinometers And Liquid Formulations
… photostability issues, Axitinib (AXI) and Sunitinib (SUT) are two new drugs only commercially available in solid dosage forms. In ethanol, the photokinetics of these drugs were well described by the newly proposed Φ-order kinetic mathematical model. This has confirmed the photoreversible …
-
Investigating the expression of plasma membrane calcium ATPase (PMCA) in patient-derived glioblastoma cultures
… Treatment with the anti-angiogenic agent sunitinib resulted in a dose-dependent upregulation of PMCA1 and downregulation of PMCA2 and PMCA4 at mRNA levels in multiple glioblastoma cell cultures, indicating that PMCA expression may be responsive to targeted therapy. Correlating PMCA …
-
Analysis of Out-of-Pocket Expenditures of Oral Oncologics for Tennessee Recipients of Medicare Part D
… lenalidomide, sorafenib, erlotinib, dasatinib, sunitinib, vorinostat, nilotinib, and lapatinib, the annual out-of-pocket costs for each drug varied from $0 to a maximum of $1,133, based on plan design. Bivariate regression analysis showed that monthly premiums, deductibles, and cost-sharing are …